Didier Landais is appointed 4P-Pharma's CEO to lead the company into a new chapter of its development
5.9.2023 11:30:00 EEST | Business Wire | Press release
4P-Pharma, a pioneering biotechnology company based in Lille and specializing in drug regeneration, is thrilled to achieve a significant milestone in its history. During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
DIDIER LANDAIS CEO - 4P-PHARMA
Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development. On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma. She now holds the position of Executive Chairwoman.
With over 30 years of international experience in the pharma/biotech industry, Didier Landais stands out as an executive leader. His career has been marked by accomplishments in key areas such as research and development, strategy, and business development.
His extensive international experience and proven leadership position Didier Landais as the ideal choice for this strategic function. His past achievements attest to his exceptional ability to guide our teams towards excellence, turning ambitious visions into tangible results. Together, the new executive will combine forces to expedite the company's development."
"We stand on the brink of a pivotal period for 4P-Pharma. The appointment of Didier reinforces our commitment to innovation and growth. His passion for scientific research, coupled with his profound market understanding, will propel forward our mission to transform how we approach health and well-being, driving dynamics of success." stated Revital Rattenbach, 4P-Pharma’s Executive Chairwoman
A strong expertise both in France and internationally, to accelerate the development of 4P-Pharma.
Didier Landais holds a Ph.D. in Molecular and Cellular Biology from the University Louis Pasteur (Strasbourg), as well as an Executive MBA from ESSEC (Paris). He started his career as a researcher and oncology project leader at the Gene Therapy Division of RPR-Gencell (Sanofi) before assuming the role of Director of Business Development and General Manager of Cell Therapy, overseeing the international development of a cancer vaccine at IDM Pharma. He has also held positions including Director of Development at Biotecnol and Chief Business Officer at Genome Profiling. Under his leadership as Global Head of Licensing, Servier concluded several notable agreements, including with Celsius, Oncodesign, and Seal Rock. More recently, he served as COO and CBO at Labgenius Ltd in London."
"Joining 4P-Pharma is a significant step for me. We are developing high-potential molecules that truly transform patients' lives. With the support of Revital and our dedicated teams, I am confident that we will reach new horizons and push the boundaries of innovation even further." expressed Didier Landais, 4P-Pharma’s CEO.
As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth. Revital Rattenbach, now 4P-Pharma’s Executive Chairwoman, remains actively involved in financial consolidation and strategic directions, ensuring the continuity of the company's founding vision.
4P-Pharma remains deeply committed to its partners, investors, and its mission to provide innovative solutions to global health challenges."
ABOUT 4P-PHARMA
4P-Pharma is a clinical stage biotech company, pioneering in drug regeneration, founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies. The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.
Website: https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
Twitter: https://twitter.com/4p_pharma
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905514097/en/
Contact information
Press
Najette Chaib – nchaib@beyondcom.fr 06 18 38 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 15:30:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, tolerability, and clinical effects of RLS-1496 1% cream in adult patients with AK on the forearms. RLS-1496 is the first selective glutathione peroxidase 4 (GPX4) modulator to be studied in human trials, and the first targeting cellular rejuvenation as a new therapeutic pathway in a novel category called Adaptive SenoTherapeutics. Interim data from the study were presented at the RBC Capital Markets Global Healthcare Conference in New York City on May 19, 2026. Preliminary RLS-1496 Actinic Keratosis Trial Results The Phase 1b/2a
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark the eighth consecutive year of wins for ExaGrid at the Networ
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 15:00:00 EEST | Press release
Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM to trace a five-step dependency chain across the real estate, and accuracy collapses. The answer arrives with confidence. The architect inherits the consequ
European DataWarehouse Launches DealDox ® , a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 15:00:00 EEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 14:47:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native environment. By enabling teams to work concurrently using shared data and standardized workflows, the approach reduces handoffs and rework and supports more consistent, timely decis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom